{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-036310","form_type":"8-K","ticker":"CNTN","cik":"0001861657","company_name":"Canton Strategic Holdings, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.994430+00:00","generated_at":"2026-05-31T04:42:49.012894+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tharimmune licenses oral infliximab from Intract Pharma for global development","bullets":["Exclusive global license (ex-South Korea) to INT-023/TH023, an oral anti-TNF-α monoclonal antibody infliximab.","Intract received upfront payment, eligible for equity-linked payments, milestones, and mid-single-digit royalties on net sales.","Tharimmune holds right of first refusal to continue development after Phase 2 trial.","Option to license Intract's Soteria/Phloral platform for up to four additional targets.","Oral formulation aims to replace IV infliximab (Remicade) for autoimmune diseases; multibillion-dollar market opportunity cited."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-036310","json":"https://secwatch.observer/filing/0001493152-24-036310.json","markdown":"https://secwatch.observer/filing/0001493152-24-036310.md","text":"https://secwatch.observer/filing/0001493152-24-036310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861657/000149315224036310/0001493152-24-036310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861657/000149315224036310/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:42:49.012894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}